IL-17 Blockade in Psoriasis.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 27984714.
- Also identified by DOI 10.1016/j.cell.2016.11.044.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
IL-17A both directly induces and synergizes with other cytokines to promote autoimmune tissue inflammation. Secukinumab and ixekizumab are monoclonal antibodies (mAb) that inhibit interleukin-17A. These two agents were recently approved for treatment of psoriasis, and secukinumab is also approved for treatment of two spondyloarthropathies, psoriatic arthritis and ankylosing spondylitis.
Medical subject headings
- Antibodies, Monoclonal
- Antibodies, Monoclonal, Humanized
- Interleukin-17
- Psoriasis